|
|
San Antonio, TX USA
phone:(210) 949-8200
fax:
|
|
| Symbol |
|
| Exchange |
|
| Founded |
0 |
| Employees |
|
|
|
| www.ilexonc.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Acquired by Genzyme Corporation. |
|
| Management |
| Jeffrey Buchalter, CEO |
| |
|
|
|
|
|
| Keywords |
| oncology, cancer, drug, pharmaceuticals, B-cell |
|
|
|
| Description |
|
Genzyme Corporation has completed its acquisition of ILEX Oncology, Inc. |
|
| Technology / Differentiation |
| Its lead product is marketed in the United States as CAMPATH and in Europe and other countries as MABCAMPATH for the treatment of patients with B-cell chronic lymphocytic leukemia. Ilex also has product candidates in clinical trials, principally addressing oncology as well as several active preclinical and drug discovery programs. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
